New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2016, Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach
View latest version (2016)Bibliographic information
GuidelineAntiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings : towards universal access : recommendations for a public health approach
Year of Publication2006
Issuing InstitutionWorld Health Organization
Recommendation
Retired
It is recommended that the triple nucleoside regimens zidovudine (AZT) + lamivudine (3TC) + abacavir (ABC) or AZT + 3TC + tenofovir disoproxil fumarate (TDF) should be used for individuals who are unable to tolerate or have contraindications to non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimens, particularly in the following situations:
- HIV/TB coinfection;
- pregnant women;
- chronic viral hepatitis B;
- HIV-2 infection.
Recommended in favor
Conditional
Certainty of evidence
Low